Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Senate FDA Appropriation Includes $2M For CBD Enforcement Discretion Policy

Sep 20 2019

• By Malcolm Spicer

WASHINGTON - JULY 18: A sign at the entrance to a Senate Appropriations Committee hearing room in Washington, DC on July 18, 2017. The US Senate is the upper chamber of the United States Congress. - Image

Related Content

Hemp Product Market Future Backed By McConnell, Fate Depends On Farm Bill

Sep 14 2018

Red Yeast Rice History Offers Blueprint For Clearing CBD As Dietary Ingredient

May 24 2019

House Appropriators Propose OTC Monograph User Fee In FDA Budget

May 28 2019

FDA Road To Decision On Expanding CBD Uses Starts With Weighing Impact On Existing And Future Use As Drug

Jun 03 2019

FDA Appropriation Targets $100,000 To Find Safe CBD Level In Supplements

Jun 24 2019

Health And Wellness On Capitol Hill: Monograph Reform, Wyden On CBD Rule, OTC Daily Contraceptive Access

Jun 26 2019

Additional Topics

United States US States Dietary Supplements Legislation FDA Advertising, Marketing & Sales Commercial Compliance Drug Approval Standards Enforcement Ingredients Manufacturing Policy Regulation Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.